Live Breaking News & Updates on Cancer Signaling Networks

Stay updated with breaking news from Cancer signaling networks. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Making Cures More Common: BIDMC Hosts 16th Annual Cancer Center Symposium

BIDMC held its 16th annual Cancer Center Symposium, focusing on targeted and immune-based cancer therapy. Learn more about this event. ....

United States , Harvard University , Richard Cummings , David Avigan , Marcella Maus , George Daley , Wenyi Wei , Dianne Silvestri , Sylvia Formenti , Michelle Wu , Irene Ghobrial , Jacalyn Rosenblatt , Ben Stanger , Michael Roehrl , S Daniel Abraham , David Mcdermott , Josephb Martin Conference Center , University Of Pennsylvania , Perelman School Of Medicine , Department Of Pathology , Umass Chan Medical School , Harvard Medical School , Division Of Hematology Hematologic Malignancies , Professor Of Medicine At Harvard Medical School , Translational Research , Cancer Center ,

Petrylak Provides Perspective on the Nationwide Cisplatin/Carboplatin Shortage

Daniel P. Petrylak, MD, discusses strategies he and his colleagues at Yale Cancer Center have employed to reduce the effect of the current chemotherapy shortage on patients, and emphasizes the need to reassess current manufacturing strategies in an effort to potentially mitigate future drug shortages. ....

United States , Danielp Petrylak , Cancer Signaling Networks At Yale Center , Yale Cancer Center , Cancer Signaling Networks , Chemotherapy Shortage ,

Erdafitinib Confers OS Benefit in FGFR-Altered Urothelial Cancer

Erdafitinib reduced the risk of death by 36% vs investigator’s choice of chemotherapy in patients with FGFR2/3-altered metastatic urothelial cancer who were previously treated with anti–PD-1 therapy, according to findings from the phase 3 THOR trial. ....

United States , France General , New Haven , Danielp Petrylak , Erdafitinib Balversa , Mamtanir Biomarker , Yohann Loriot , Early Trials Department At Gustave Roussy Institute , Cancer Signaling Networks At Yale Center , University Paris , Therapeutic Innovation , Early Trials Department , Gustave Roussy Institute , University Paris Saclay , Cancer Signaling Networks , Yale Cancer Center , Urothelial Cancer , Fgfr Altered Urothelial Cancer , Author Trial , Asco Annual Meeting , University Paris Saclay ,

Astellas and Seagen Announce Initial Results of PADCEV® (enfortumab vedotin-ejfv) in Patients With Muscle-Invasive Bladder Cancer Not Eligible for Cisplatin Chemotherapy

/PRNewswire/ Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Seagen Inc. (Nasdaq:SGEN) today announced the initial. ....

United States , Kenji Yasukawa , Daniel Petrylak , Ahsan Arozullah , Enfortumab Vedotin , Cancer Signaling Networks , Urology Care Foundation , Astellas Pharma Us Inc , Yale Cancer Center , Seagen Inc , Stage Development , Exchange Commission , Astellas Pharma Inc , European Union , Most Common Adverse Reactions Including Laboratory Abnormalities , Prnewswire Astellas Pharma Inc , Cancers Symposium , Important Safety Information , Vice President , Medical Sciences Oncology , Yale School , Medicine Professor , Medical Oncology , Marjorie Green , Senior Vice President , Late Stage Development ,

Astellas and Seagen Announce Initial Results of PADCEV® (enfortumab vedotin-ejfv) in Patients With Muscle-Invasive Bladder Cancer Not Eligible for Cisplatin Chemotherapy

/PRNewswire/ Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Seagen Inc. (Nasdaq:SGEN) today announced the initial. ....

United States , Kenji Yasukawa , Daniel Petrylak , Ahsan Arozullah , Enfortumab Vedotin , Cancer Signaling Networks , Urology Care Foundation , Astellas Pharma Us Inc , Yale Cancer Center , Seagen Inc , Stage Development , Exchange Commission , Astellas Pharma Inc , European Union , Most Common Adverse Reactions Including Laboratory Abnormalities , Prnewswire Astellas Pharma Inc , Cancers Symposium , Important Safety Information , Vice President , Medical Sciences Oncology , Yale School , Medicine Professor , Medical Oncology , Marjorie Green , Senior Vice President , Late Stage Development ,